Link Biosystems Inc.
Irvington, NY
- UEI
- XML9QKHWRPR3
- CAGE
- 96RQ8
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- NAICS codes registered in SAM.gov
- SAM.gov registration date
- Physical address
- 15 Sycamore Ln, Irvington, NY 10533, USA
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Recent federal awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| Efficient scale-up of IPS cells for autologous cell therapy workflow - project summary/abstract cell expansion is a… | National Cancer Institute | $258,073 | |
| Efficient differentiation, scale-up, and maturation of IPS derived cardiomyocytes - project summary/abstract cell… | National Heart Lung and Blood Institute | $275,396 | |
| Cell expansion bioreactors for assay-ready immunocompetent patient models - project summary/abstract although cancer… | National Cancer Institute | $3,535,267 | |
| Cell expansion bioreactors for assay-ready immunocompetent patient models - project summary/abstract although cancer… | National Cancer Institute | $600,534 |
About Link Biosystems Inc.
Link Biosystems Inc. is a self-certified small disadvantaged business and corporate for-profit organization registered to receive federal awards. The entity develops bioreactor technologies and workflows for efficient cell expansion, differentiation, and maturation to support cell therapy, disease modeling, and drug development applications.
Link Biosystems Inc. has received multiple federal grant awards from the National Institutes of Health (NIH) to further develop its bioreactor platforms. A $275,627 grant from the National Cancer Institute supports the ONXPANSION bioreactor workflow to expand patient-derived induced pluripotent stem cells into clinically relevant doses for autologous cell therapies. Under the Cardiovascular Diseases Research program, a $275,396 award aids in differentiating and maturing induced pluripotent stem cell-derived cardiomyocytes using low-shear perfusion bioreactors for cell therapy and disease modeling applications. Additionally, a $600,534 grant from the National Cancer Institute funds the development of bioreactors to generate large quantities of "immunocompetent tumoroid tissues" from patient tumor samples for preclinical drug screening, including testing of immunotherapies, biologics, and drug combinations to identify optimal treatment regimens tailored to specific patient populations. Link Biosystems Inc.'s bioreactor platforms leverage controlled cell aggregation, low-shear perfusion, organotypic niches, and serum-free media to enable efficient and scalable expansion, differentiation, and maturation of various cell types while reducing costs and labor compared to conventional methods.
Quick answers
What is Link Biosystems Inc.'s UEI?
Link Biosystems Inc.'s Unique Entity ID (UEI) in SAM.gov is XML9QKHWRPR3.
What is Link Biosystems Inc.'s CAGE code?
Link Biosystems Inc.'s CAGE code is 96RQ8.
What is Link Biosystems Inc.'s primary NAICS code?
Link Biosystems Inc.'s primary NAICS code is 541714 (Research and Development in Biotechnology (except Nanobiotechnology)).
Where is Link Biosystems Inc. located?
Link Biosystems Inc.'s physical address in SAM.gov is 15 Sycamore Ln, Irvington, NY 10533, USA.
Is Link Biosystems Inc. registered in SAM.gov?
Yes. Link Biosystems Inc.'s SAM.gov registration is active through June 15, 2027.
What is Link Biosystems Inc.'s most recent federal award?
Link Biosystems Inc.'s most recent federal grant award is Efficient scale-up of IPS cells for autologous cell therapy workflow - project summary/abstract cell expansion is a… (R43CA285143), from National Cancer Institute, on September 15, 2023.
On GovTribe
See Link Biosystems Inc.'s full federal record
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors